Roy S. Herbst MD, PhD

Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven; Associate Director for Translational Research, Yale Cancer Center; Clinical Research Program Leader, Thoracic Oncology Program, Yale Cancer Center


Departments & Organizations

Cancer Center, Yale: Thoracic Oncology Program | Developmental Therapeutics

Pharmacology

Medical Oncology

Biography

Dr. Herbst is nationally recognized for his leadership and expertise in lung cancer treatment and research. He is best known for his work in developmental therapeutics and the personalized therapy of non-small cell lung cancer, in particular the process of linking genetic abnormalities of cancer cells to novel therapies.

He is a member of the American Association for Cancer Research (AACR), where he chairs the Tobacco Task Force, as well as the American Society of Clinical Oncology and the Institute of Medicine’s National Cancer Policy Forum. He is a fellow of the American College of Physicians. Dr. Herbst is also a vice chair of the Southwest Oncology Group’s lung committee, a member of the medical advisory committee for the Lung Cancer Research Foundation and chair of the communications committee for the International Association for the Study of Lung Cancer. He has authored more than 200 peer-reviewed papers and has current grant funding for his work from numerous sources including the National Cancer Institute, AACR and multiple charitable foundations.

Dr. Herbst received his medical degree from Cornell University Medical College and earned a Ph.D. in molecular cell biology from the Rockefeller University. He completed his medical oncology fellowship at Dana Farber Cancer Institute and a medical hematology fellowship at Brigham and Women’s Hospital in Boston, where he additionally received a master’s degree from Harvard University in their clinical investigator training program.


Education

  • M.S., Yale University , 1984
  • B.S., Yale University , 1984
  • Ph.D., Rockefeller University , 1990
  • M.D., Cornell University Medical College , 1991
  • MMS, Harvard University , 1997

Selected Publication

  • Multitargeted tyrosine kinase inhibitors in unselected patients with advanced non-small-cell lung cancer (NSCLC): impressions from MONET (the motesanib NSCLC efficacy and tolerability study). Morgensztern D, Herbst RS. J Clin Oncol. 2012 Aug 10;30(23):2805-8.

Latest Honor and Recognition

  • Honorary Professor, University College London Cancer Center (2012) , University College London
Download on the Apple App Store